Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor's Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 2028. The new patent term is approximately three years longer than the previous latest-to-expire U.S. patent covering.

Business Wire • Dec 9, 2025

Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen Immunology and Inflammation Virtual Summit Date: Wednesday, November 12, 2025 Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT Piper Sandler 37th Annual Healthcare Conference Date: Tuesday, December.

Business Wire • Nov 10, 2025

Xencor Reports Third Quarter 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates. “Xencor's two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and XmAb541, have demonstrated compelling clinical data in advanced clear cell r.

Business Wire • Nov 5, 2025

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor, Inc. (NASDAQ:XNCR ) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma October 24, 2025 1:30 PM EDT Company Participants Charles Liles - Associate Director and Head of Corporate Communications & Investor Relations Bassil Dahiyat - Co-Founder, CEO, President & Director John Desjarlais - Executive VP of Research & Chief Scientific Officer Dane Leone - Executive VP & Chief Strategy Officer Conference Call Participants Sumanta Kumar Pal Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Jonathan Chang - Leerink Partners LLC, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Tara Bancroft - TD Cowen, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Alec Stranahan - BofA Securities, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Presentation Operator Good day, everyone.

Seeking Alpha • Oct 24, 2025

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented in a poster at the AACR-NCI-EORTC Conference on Molecular Targets and C.

Business Wire • Oct 24, 2025

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma.

Business Wire • Oct 21, 2025

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation of initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC) in a poster at the AACR-NCI-EORTC Conference on Molecular Targets an.

Business Wire • Oct 14, 2025

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Xencor remains a "Strong Buy" rating due to progress in its bispecific and monospecific antibody pipeline targeting inflammatory disorders and cancer. XNCR's XmAb942 anti-TL1A antibody is advancing toward a phase 2b trial in ulcerative colitis in 2nd half of 2025, with positive interim safety and biomarker data already reported. XmAb819, a 2+1 bispecific antibody for relapsed/refractory ccRCC, has shown early anti-tumor activity; initial phase 1 data is expected in Q4 2025.

Seeking Alpha • Sep 19, 2025

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Sep 18, 2025